To overcome data silos in a regulated environment, CIBC prioritized building internal trust. They proactively brought legal, compliance, and privacy teams together, clearly defining the use case and value of unified data, which was critical for gaining enterprise-wide approval.

Many firms view patient engagement as a compliance task that adds cost. However, data shows integrating patient experience into development from the start speeds up clinical trial recruitment and execution, reduces FDA amendments, and accelerates time-to-market, providing clear ROI.

A company can build a significant competitive advantage in healthcare by deliberately *not* touching or seeing Protected Health Information (PHI). Focusing exclusively on metadata reduces regulatory overhead and security risks, allowing the business to solve the critical problem of data orchestration and intelligence, a layer often neglected by data aggregators.

Instead of viewing compliance (like HIPAA or PII rules) as a barrier, companies in regulated sectors should use it as a strategic filter. This forces the selection of mature, enterprise-scale partners from the outset, avoiding pilots with vendors that can't pass production-level scrutiny.

Regulatory oversight is poised to shift from punitive, after-the-fact audits to a collaborative model. AI systems could provide a standardized, real-time audit report accessible to both the manufacturer and the regulator. This transparency allows for proactive issue resolution, with regulators acting as guides rather than just enforcers.

While speed is crucial in clinical trials, the ability to transfer data across borders is a growing pain point. Data privacy regulations, particularly in China, complicate due diligence and global collaboration, making data portability a key factor for efficiency and a significant hurdle for M&A.

The traditional transactional model where AI companies purchase pharma data is ending. To resolve the stalemate where AI needs trial data and trials need validated AI, the industry is shifting to strategic partnerships. In these collaborations, both parties jointly generate evidence during trials, accelerating development and providing mutual benefit.

Roloff wants to turbocharge reuse of clinical trial data so it can be reanalyzed for other diseases. He expects secure collaboration within three to five years to make virtual trials using reused data less expensive for pharma and the FDA to accept, which could reshape drug research and development.

To scale its database from millions to tens of millions, Regeneron is moving beyond bespoke global studies. The new model involves large-scale partnerships with health systems and consumer data sources, using privacy-preserving tokenization to securely link genetic data with vast electronic health records.